References
- Bottorff, J. L., Johnson, J. L., Moffat, B. M., & Mulvogue, T. (2009). Relief-oriented use of marijuana by teens. Substance Abuse Treatment Prevention and Policy, 4(1), 7. doi:10.1186/1747-597X-4-7
- Degenhardt, L., Coffey, C., Romaniuk, H., Swift, W., Carlin, J. B., Hall, W. D., & Patton, G. C. (2013). The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction, 108(1), 124–133. doi:10.1111/j.1360-0443.2012.04015.x
- European Monitoring Centre for Drugs and Drug Addiction. (2018). Medical use of cannabis and cannabinoids: Questions and answers for policymaking. Luxembourg: Publications Office of the European Union.
- Findlay, L. (2017). Health reports: Depression and suicidal ideation among Canadians aged 15 to 24. Retrieved from https://www150.statcan.gc.ca/n1/pub/82-003-x/2017001/article/14697-eng.htm. Accessed 28 July 2018.
- Government of Canada. (2016). A framework for the legalization and regulation of cannabis in Canada: The final report of the task force on cannabis legalization and regulation. Retrieved from https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/laws-regulations/task-force-cannabis-legalization-regulation/framework-legalization-regulation-cannabis-in-canada.html#a5.
- Government of Canada. (2018a). Cannabis for medical purposes under the Cannabis Act: Information and improvements. Retrieved from https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/medical-use-cannabis.html.
- Government of Canada. (2018b). Cannabis Act (S.C. 2018, c.16) Ottawa, ON. Retrieved from https://laws-lois.justice.gc.ca/eng/acts/c-24.5/.
- Government of Canada. (2019a). Cannabis health warning messages: Updates for October 2019. Retrieved from https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/laws-regulations/regulations-support-cannabis-act/health-warning-messages.html.
- Government of Canada. (2019b). Regulations amending the cannabis regulations (New classes of cannabis): SOR/2019-206. Retrieved from http://www.gazette.gc.ca/rp-pr/p2/2019/2019-06-26/html/sor-dors206-eng.html.
- Groves, R. M., Fowler, F. J., Couper, M. P., Lepkowski, J. M., Singer, E., & Tourangeau, R. (2009). Survey methodology (2nd ed.). Hoboken, NJ: Wiley.
- Hall, W., & Weier, M. (2015). Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clinical Pharmacology & Therapeutics, 97(6), 607–615. doi:10.1002/cpt.110
- Hammond, D., & Reid, J. L. (2018). Exposure and perceptions of marketing for caffeinated energy drinks among young Canadians. Public Health Nutrition, 21(03), 535–542. doi:10.1017/S1368980017002890
- Health Canada. (2016a). Understanding the new access to cannabis for medical purposes regulations. Retrieved from https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/understanding-new-access-to-cannabis-for-medical-purposes-regulations.html.
- Health Canada. (2016b). Consumer information—Cannabis (Marihuana, Marijuana). Retrieved from https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/licensed-producers/consumer-information-cannabis.html.
- Health Canada. (2017a). Canadian tobacco alcohol and drugs survey 2015. Retrieved from https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-survey/2015-supplementary-tables.html.
- Health Canada. (2017b). Proposed approach to the regulation of cannabis. Retrieved from https://www.canada.ca/en/health-canada/programs/consultation-proposed-approach-regulation-cannabis/proposed-approach-regulation-cannabis.html.
- Health Canada. (2017c). Canadian cannabis survey 2017. Retrieved from https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/canadian-cannabis-survey-2017-summary.html.
- Health Canada. (2018a). Authorized licensed producers of cannabis for medical purposes. Retrieved from https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/licensed-producers/authorized-licensed-producers-medical-purposes.html.
- Health Canada. (2018b). Licensed producers: Market data. Retrieved from https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/licensed-producers/market-data.html.
- Hill, K. P. (2015). Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: A clinical review. JAMA Psychiatry, 313(24), 2474–2483. doi:10.1001/jama.2015.6199
- Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemistry & Biodiversity, 4(8), 1770–1804. doi:10.1002/cbdv.200790152
- Kosiba, J. D., Maisto, S. A., & Ditre, J. W. (2019). Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis. Social Science & Medicine, 233, 181–192. doi:10.1016/j.socscimed.2019.06.005
- Krumpal, I. (2013). Determinants of social desirability bias in sensitive surveys: A literature review. Quality & Quantity, 47, 2025–2047. doi:10.1007/s11135-011-9640-9
- Leos-Toro, C., Shiplo, S., & Hammond, D. (2018). Perceived support for medical cannabis use among approved medical cannabis users in Canada. Drug and Alcohol Review, 37(5), 627–636. doi:10.1111/dar.12823
- Lev-Ran, S., Roerecke, M., Le Foll, B., George, T. P., McKenzie, K., & Rehm, J. (2014). The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. Psychological Medicine, 44(4), 797–810. doi:10.1017/S0033291713001438
- Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. The Lancet, 370(9584), 319–328. doi:10.1016/S0140-6736(07)61162-3
- Murray, R. M., Quigley, H., Quattrone, D., Englund, A., & Di Forti, M. (2016). Traditional marijuana, high‐potency cannabis and synthetic cannabinoids: Increasing risk for psychosis. World Psychiatry, 15(3), 195–204. doi:10.1002/wps.20341
- National Academies of Sciences, Engineering, and Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press.
- Niesink, R. J., & van Laar, M. W. (2013). Does cannabidiol protect against adverse psychological effects of THC? Frontiers in Psychiatry, 4, 130. doi:10.3389/fpsyt.2013.00130
- NORML. (2019). State laws: Medical marijuana. Retrieved from https://norml.org/legal/medical-marijuana-2.
- Pacula, R., Jacobson, M., & Maksabedian, E. (2016). In the weeds: A baseline view of cannabis use among legalizing states and their neighbours. Addiction, 111(6), 973. doi:10.1111/add.13282
- Schofield, D., Tennant, C., Nash, L., Degenhardt, L., Cornish, A., Hobbs, C., & Brennan, G. (2006). Reasons for cannabis use in psychosis. Australian and New Zealand Journal of Psychiatry, 40(6–7), 570–574. doi:10.1080/j.1440-1614.2006.01840.x
- Semple, D. M., McIntosh, A. M., & Lawrie, S. M. (2005). Cannabis as a risk factor for psychosis: Systematic review. Journal of Psychopharmacology, 19(2), 187–194. doi:10.1177/0269881105049040
- Statistics Canada. (2019). Table 17-10-0005-01. Population estimates on July 1st, by age and sex, 2017. Retrieved from https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000501.
- Stockings, E., Zagic, D., Campbell, G., Weier, M., Hall, W. D., Nielsen, S., … Degenhardt, L. (2018). Evidence for cannabis and cannabinoids for epilepsy: A systematic review of controlled and observational evidence. Journal of Neurology, Neurosurgery & Psychiatry, 89(7), 741–753. doi:10.1136/jnnp-2017-317168
- Volkow, N. D., Swanson, J. M., Evins, A. E., DeLisi, L. E., Meier, M. H., Gonzalez, R., … Baler, R. (2016). Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: A review. JAMA Psychiatry, 73(3), 292–297. doi:10.1001/jamapsychiatry.2015.3278
- Walsh, Z., Callaway, R., Belle-Isle, L., Capler, R., Kay, R., Lucas, P., & Holtzman, S. (2013). Cannabis for therapeutic purposes: Patient characteristics, access, and reasons for use. International Journal of Drug Policy, 24(6), 511–516. doi:10.1016/j.drugpo.2013.08.010
- Walsh, Z., Gonzalez, R., Crosby, K., Thiessen, M. S., Carroll, C., & Bonn-Miller, M. O. (2017). Medical cannabis and mental health: A guided systematic review. Clinical Psychology Review, 51, 15–29. doi:10.1016/j.cpr.2016.10.002
- Watson, T., Hyshka, E., Bonato, S., & Rueda, S. (2019). Early-stage cannabis regulatory policy planning across Canada’s four largest provinces: A descriptive overview. Substance Use and Misuse, 54(10), 1690–1704.
- Wiggers, D., Reid, J. L., White, C. M., & Hammond, D. (2017). Use and perceptions of caffeinated energy drinks and energy shots in Canada. American Journal of Preventive Medicine, 53(6), 866–871. doi:10.1016/j.amepre.2017.05.021
- Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … Kleijnen, J. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. Journal of American Medical Association, 313(24), 2456–2473. doi:10.1001/jama.2015.6358